What does SASMAR PHARMACEUTICALS do?

SASMAR PHARMACEUTICALS is a wholesaler in Overijse. Private Limited, started on 22 December 2014, 1 establishment.

What is the address of SASMAR PHARMACEUTICALS?

The registered office of SASMAR PHARMACEUTICALS is located at Sint-Hubertusdreef 26, 3090 Overijse.

Is SASMAR PHARMACEUTICALS still active?

Yes. According to the CBE (30 September 2026) SASMAR PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 22 December 2014.

Is SASMAR PHARMACEUTICALS registered on Peppol?

Yes, SASMAR PHARMACEUTICALS is registered on the Peppol network with ID 0208:0507657022.

What is the enterprise number of SASMAR PHARMACEUTICALS?

The enterprise number of SASMAR PHARMACEUTICALS is BE0507657022.

When was SASMAR PHARMACEUTICALS founded?

SASMAR PHARMACEUTICALS was founded on 22 December 2014.

Is SASMAR PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 December 2014; 4 annual accounts filed, latest fiscal year 2024.

How much profit did SASMAR PHARMACEUTICALS make in 2024?

SASMAR PHARMACEUTICALS recorded a loss after taxes of € 97,001 in financial year 2024.

What is the revenue of SASMAR PHARMACEUTICALS?

In its most recent annual accounts (2024), SASMAR PHARMACEUTICALS reported revenue of € 1,965,734.

How much does an employee at SASMAR PHARMACEUTICALS earn?

The average wage cost per full-time employee at SASMAR PHARMACEUTICALS was € 77,700 in 2024: staff costs of € 342,037 for 4.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does SASMAR PHARMACEUTICALS have?

According to the 2024 annual accounts, SASMAR PHARMACEUTICALS has 4.4 full-time equivalents (FTE).

SASMAR PHARMACEUTICALS (Private Limited) - Overijse

Dossier SASMAR PHARMACEUTICALS, printed on 30 September 2026 from databakkes.be/en/0507657022/sasmar-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 18 % of short-term debt in 2024; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2022.

Financials

Financial year 2024

SASMAR PHARMACEUTICALS from Overijse, company number BE0507657022, closed financial year 2024 with a result of € -97,001 after tax. For that financial year SASMAR PHARMACEUTICALS recorded revenue of € 2 million and equity of € 246,140. Compared with financial year 2023, the result moved from € 61,513 to € -97,001. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 26, 2025.

What it is worth Healthy

€ 246,140

▼ 28% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -97,001

▼ still € 61,513 profit in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 10,947

▼ 41% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 227,540.

People and assets in 2024

Full-time equivalents

4.4

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 342,037

▼ 6% vs 2023

€ 77,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,766

▼ 91% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

€ 3,399

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2.1 million

▼ 28% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 74,748

▼ 2% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	-	-	€ 2,417,037 Revenue 2023: € 2,417,037 First fiscal year in the series	€ 1,965,734 Revenue 2024: € 1,965,734 ▼ 19% vs 2023 (€ 2,417,037) Unfavourable step	▼ 19%
Gross margin	€ 1,273,126 Gross margin 2021: € 1,273,126 First fiscal year in the series	€ 820,919 Gross margin 2022: € 820,919 ▼ 36% vs 2021 (€ 1,273,126) Unfavourable step	€ 471,594 Gross margin 2023: € 471,594 ▼ 43% vs 2022 (€ 820,919) Unfavourable step	€ 366,473 Gross margin 2024: € 366,473 ▼ 22% vs 2023 (€ 471,594) Unfavourable step	▼ 22%
Profit after taxes	€ 362,640 Profit after taxes 2021: € 362,640 First fiscal year in the series	€ -234,325 Profit after taxes 2022: € -234,325 ▼ € 596,965 vs 2021 (€ 362,640) Unfavourable step	€ 61,513 Profit after taxes 2023: € 61,513 ▲ € 295,838 vs 2022 (€ -234,325) Favourable step	€ -97,001 Profit after taxes 2024: € -97,001 ▼ € 158,514 vs 2023 (€ 61,513) Unfavourable step	▼ € 158,514
Equity	€ 515,953 Equity 2021: € 515,953 First fiscal year in the series	€ 281,628 Equity 2022: € 281,628 ▼ 45% vs 2021 (€ 515,953) Unfavourable step	€ 343,141 Equity 2023: € 343,141 ▲ 22% vs 2022 (€ 281,628) Favourable step	€ 246,140 Equity 2024: € 246,140 ▼ 28% vs 2023 (€ 343,141) Unfavourable step	▼ 28%
Total debts	€ 842,028 Total debts 2021: € 842,028 First fiscal year in the series	€ 1,360,648 Total debts 2022: € 1,360,648 ▲ 62% vs 2021 (€ 842,028) Unfavourable step	€ 3,076,435 Total debts 2023: € 3,076,435 ▲ 126% vs 2022 (€ 1,360,648) Unfavourable step	€ 2,949,624 Total debts 2024: € 2,949,624 ▼ 4% vs 2023 (€ 3,076,435) Favourable step	▼ 4%
Cash	€ 44,746 Cash 2021: € 44,746 First fiscal year in the series	€ 14,213 Cash 2022: € 14,213 ▼ 68% vs 2021 (€ 44,746) Unfavourable step	€ 18,478 Cash 2023: € 18,478 ▲ 30% vs 2022 (€ 14,213) Favourable step	€ 10,947 Cash 2024: € 10,947 ▼ 41% vs 2023 (€ 18,478) Unfavourable step	▼ 41%
Land & buildings	-	-	€ 7,384 Land & buildings 2023: € 7,384 First fiscal year in the series	-
Retained profit	€ 497,353 Retained profit 2021: € 497,353 First fiscal year in the series	€ 263,028 Retained profit 2022: € 263,028 ▼ 47% vs 2021 (€ 497,353) Unfavourable step	€ 324,541 Retained profit 2023: € 324,541 ▲ 23% vs 2022 (€ 263,028) Favourable step	€ 227,540 Retained profit 2024: € 227,540 ▼ 30% vs 2023 (€ 324,541) Unfavourable step	▼ 30%
Bank debt	€ 4,692 Bank debt 2021: € 4,692 First fiscal year in the series	€ 610,237 Bank debt 2022: € 610,237 ▲ € 605,545 vs 2021 (€ 4,692) Unfavourable step	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 610,237) Favourable step	€ 3,399 Bank debt 2024: € 3,399 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 1,357,981 Balance sheet total 2021: € 1,357,981 First fiscal year in the series	€ 1,642,276 Balance sheet total 2022: € 1,642,276 ▲ 21% vs 2021 (€ 1,357,981) Unchanged	€ 3,419,576 Balance sheet total 2023: € 3,419,576 ▲ 108% vs 2022 (€ 1,642,276) Unchanged	€ 3,195,764 Balance sheet total 2024: € 3,195,764 ▼ 7% vs 2023 (€ 3,419,576) Unchanged	▼ 7%
Employees (FTE)	-	-	-	4.4 Employees (FTE) 2024: 4.4 First fiscal year in the series

Key figures of SASMAR PHARMACEUTICALS, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to SASMAR PHARMACEUTICALS?

What happened at SASMAR PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 26, 2025 New annual accounts for financial year 2024: loss of € 97,001 (▼ € 158,514 vs 2023). filed late Source: NBB ↗
Dec 22, 2014 New establishment in Overijse. KBO
Dec 22, 2014 Start of the company according to the CBE. KBO

In short

From € 362,640 profit in 2021 to € 97,001 loss in 2024.

Best year ever: 2021, with € 362,640 profit.

On average € 83,300 of value added per employee in 2024.

Original PDFs at the National Bank ↗

A new publication or filing at SASMAR PHARMACEUTICALS? We notify you, reason included.

Follow SASMAR PHARMACEUTICALS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Sint-Hubertusdreef 26

3090 Overijse

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0507.657.022

VAT number

BE 0507.657.022

Registered office

Sint-Hubertusdreef 26, 3090 Overijse

Names & denominations

SASMAR PHARMACEUTICALS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 December 2014

Peppol

Active · Active since 8 Jan 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗